Iovance Biotherapeutics, Inc. IOVA Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s total costs & expenses?
- Iovance Biotherapeutics, Inc. (IOVA) reported total costs & expenses of $152.47M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s total costs & expenses changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total costs & expenses decreased by 10.6% year-over-year, from $170.55M to $152.47M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total costs & expenses?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s total costs & expenses has grown at a 18.1% compound annual growth rate (CAGR), from $342.7M to $666.86M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating and non-operating costs incurred by the company during a reporting period. It encompasses cost of revenue, research and development, general and administrative expenses, and other operational charges. Monitoring this figure is essential for assessing the company's overall burn rate and operational efficiency as it scales toward commercialization.